Salman Khalid, MD
Interventional Cardiology · Oklahoma City, OKNPI 1477832806
Payments from drug & device makers
Across 83 payments — averaging $76.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$2K
- Abiomed$605
- Medtronic$233
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$198
- Johnson & Johnson$57
- plus $455 from 14 others
What the payments were for
- Travel & lodging$4,08864%
- Food & beverage$2,27236%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 21 | $2,996 |
| Boston Scientific | 13 | $1,815 |
| Abiomed | 9 | $605 |
| Medtronic | 3 | $233 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $198 |
| Johnson & Johnson | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| Novartis | 3 | $56 |
| Scpharmaceuticals Inc. | 3 | $54 |
| Inari Medical, Inc. | 3 | $51 |
| AstraZeneca | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Philips North America LLC | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| Pfizer | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,609
- TRICLIP$1,052
- GENERAL VASCULAR ACCESS$842
- Impella$411
- COREVALVE EVOLUT R$129
How this compares
$6,360 in reported general payments places this provider in the 45th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 194 | $172,461 |
| EntrestoSacubitril/Valsartan | 72 | $68,101 |
| XareltoRivaroxaban | 18 | $21,890 |
| BrilintaTicagrelor | 45 | $19,603 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,517 |
| Mexiletine Hcl | 11 | $2,142 |
| Metoprolol Succinate | 227 | $2,050 |
| Atorvastatin Calcium | 272 | $1,887 |
| Ranolazine ErRanolazine | 31 | $1,837 |
| Potassium Chloride | 83 | $1,195 |
| Carvedilol | 126 | $878 |
| Pantoprazole Sodium | 25 | $809 |
| Amlodipine Besylate | 177 | $801 |
| ClopidogrelClopidogrel Bisulfate | 90 | $785 |
| Furosemide | 158 | $707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $172,461194 claims |
| NovartisEntresto | $56 | $68,10172 claims |
| Johnson & JohnsonXarelto | $57 | $21,89018 claims |
| AstraZenecaBrilinta | $45 | $19,60345 claims |
| Boehringer IngelheimCombivent Respimat | $18 | $5,51711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- Naeem TahirkheliOklahoma City$8.6M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Usman BaberOklahoma City$736K
- Jeffrey SparlingOklahoma City$381K
- Thomas McGarryOklahoma City$153K
- Faisal LatifOklahoma City$129K
- Branislav SchifferdeckerOklahoma City$121K
- Mazen Abu-FadelOklahoma City$98K
- Dwayne SchmidtOklahoma City$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.